{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=106",
    "query": {
      "intervention": "CTRL",
      "page": 106
    },
    "page_size": 10
  },
  "pagination": {
    "page": 106,
    "page_size": 10,
    "total_count": 26682,
    "total_pages": 2669,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=107&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTRL&page=105&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T01:43:12.170Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01248468",
      "title": "Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pain, Migraine"
      ],
      "interventions": [
        {
          "name": "Aspirin, acetaminophen and caffeine",
          "type": "DRUG"
        },
        {
          "name": "Sumatriptan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 752,
      "start_date": "2010-11",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-07-30",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 20,
      "location_summary": "Anaheim, California • San Francisco, California • Clearwater, Florida + 17 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01248468"
    },
    {
      "nct_id": "NCT03509350",
      "title": "Vitamin C, Thiamine, and Steroids in Sepsis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sepsis"
      ],
      "interventions": [
        {
          "name": "Vitamin C",
          "type": "DRUG"
        },
        {
          "name": "Thiamine",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "Vitamin C Placebo",
          "type": "DRUG"
        },
        {
          "name": "Thiamine Placebo",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 501,
      "start_date": "2018-08-22",
      "completion_date": "2020-01-29",
      "has_results": true,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 43,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03509350"
    },
    {
      "nct_id": "NCT06605950",
      "title": "A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "KarXT",
          "type": "DRUG"
        },
        {
          "name": "KarX-EC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karuna Therapeutics, Inc., a Bristol Myers Squibb company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "19 Years to 90 Years"
      },
      "enrollment_count": 78,
      "start_date": "2024-10-01",
      "completion_date": "2025-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06605950"
    },
    {
      "nct_id": "NCT02605174",
      "title": "Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine With or Without Aura"
      ],
      "interventions": [
        {
          "name": "Lasmiditan 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Lasmiditan 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Lasmiditan 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3005,
      "start_date": "2016-05",
      "completion_date": "2017-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-09-23",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605174"
    },
    {
      "nct_id": "NCT02936297",
      "title": "Gluten Ingestion Biomarkers in Patients w Gluten Sensitivity and Healthy Controls Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non Celiac Gluten Sensitivity"
      ],
      "interventions": [
        {
          "name": "High dose Gluten",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low dose Gluten",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lactose free placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 90,
      "start_date": "2016-06",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02936297"
    },
    {
      "nct_id": "NCT00802997",
      "title": "Trial Assessing Cooled Radiofrequency Denervation as a Treatment for Sacroiliac Joint Pain Using the Sinergy System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Other Acute Pain",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "Sinergy",
          "type": "DEVICE"
        },
        {
          "name": "Placebo sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Baylis Medical Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2008-06",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2014-01-01",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 1,
      "location_summary": "Bradenton, Florida",
      "locations": [
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00802997"
    },
    {
      "nct_id": "NCT07269210",
      "title": "A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Solbinsiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07269210"
    },
    {
      "nct_id": "NCT03242720",
      "title": "Effects of PAP on Afib Recurrence Risk After Catheter Ablation in OSA Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obstructive Sleep Apnea",
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Cardiac Ablation for Atrial Fibrillation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-01-01",
      "completion_date": "2020-12",
      "has_results": false,
      "last_update_posted_date": "2022-05-24",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 1,
      "location_summary": "Redwood City, California",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03242720"
    },
    {
      "nct_id": "NCT01963208",
      "title": "Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Drug Resistant Partial Onset Seizure"
      ],
      "interventions": [
        {
          "name": "ganaxolone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marinus Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 405,
      "start_date": "2013-10",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2023-02-14",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01963208"
    },
    {
      "nct_id": "NCT01647308",
      "title": "Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "ISIS-APOCIIIRX",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-07",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2022-01-18",
      "last_synced_at": "2026-11-13T01:43:12.170Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647308"
    }
  ]
}